Pasar al contenido principal

El patrón bioquímico define fenotipos de enfermedad hepática metabólica asociados a una distinta histología, patogénesis y pronóstico (NAphen Study)

PI22/01345

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i en Salud
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACION EN SALUD DE SEVILLA
Centro realización FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACION EN SALUD DE SEVILLA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel insights into metabolic-associated steatotic liver disease preclinical models

  • Montero-Vallejo, Rocío
  • Maya-Miles, Douglas
  • Ampuero, Javier
  • Martín, Franz
  • Romero-Gómez, Manuel
  • Gallego-Durán, Rocío
© 2024 The Authors. Liver International published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made., Metabolic-associated steatotic liver disease (MASLD) encompasses a wide spectrum of metabolic conditions associated with an excess of fat accumulation in the liver, ranging from simple hepatic steatosis to cirrhosis and hepatocellular carcinoma. Finding appropriate tools to study its development and progression is essential to address essential unmet therapeutic and staging needs. This review discusses advantages and shortcomings of different dietary, chemical and genetic factors that can be used to mimic this disease and its progression in mice from a hepatic and metabolic point of view. Also, this review will highlight some additional factors and considerations that could have a strong impact on the outcomes of our model to end up providing recommendations and a checklist to facilitate the selection of the appropriate MASLD preclinical model based on clinical aims., The research leading to these results has received funding from the Consejería de Salud de la Junta de Andalucía under grant agreement PC-0148-2016-0148 and PE-0451-2018, and from the Instituto de Salud Carlos III under grant agreements CD21/00095, PI19/01404, PI19/00589, PI22/01342, PI22/01345 and IFI18/00041 and Ministerio de Economía y Competitividad under grant agreement AGL-2017-86927-R and PID2020-116731RB-C21. Rocío Montero-Vallejo has received the Juan Manuel Herrerías from Sociedad Andaluza de Patología Digestiva, CIBERehd grants to support mobility and improve mice handling. Rocío Gallego-Durán has received the Andrew K Burroughs Fellowship from European Association for the Study of the Liver (EASL), Aprendizaje de Nuevas Tecnologías fellowship from Asociación Española para el Estudio del Hígado (AEEH) and CIBERehd Grant to support researcher's mobility., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease

  • Priego-Parra, Bryan Adrián
  • Gallego-Durán, Rocío
  • Román-Calleja, Berenice M.
  • Velarde-Ruiz Velasco, José Antonio
  • Romero-Gómez, Manuel
  • Gracia-Sancho, Jordi
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), has become a pressing global health concern. The complexity of MASLD and the lack of universally effective treatments expose the limitations of current interventions, which focus mainly on lifestyle modifications. Here, we explore the multilayered nature of MASLD, emphasizing its pathophysiology in shaping future medical and lifestyle interventions from a personalized medicine perspective, based on individual molecular profiles. Additionally, we address the limitations of current animal models in reflecting human metabolic syndrome and sex-specific differences. We argue that a holistic approach, integrating social determinants of health, patient preferences, and adherence patterns, is essential for advancing MASLD management effectively., Authors acknowledge continuous funding from the Instituto de Salud Carlos III (ISCIII; currently PI23/00945, DTS22/00010 & DTS24/00035 to J.G.-S., CD21/00095, PI22/01342, PI22/01345 and PI24/02008 to R.G.-D. and M.R.-G., all co-funded by the European Union), the AGAUR-Generalitat de Catalunya (2021 SGR 01322 & 2021 PROD 00036) to J.G.-S and the CIBEREHD. CIBEREHD is funded by the Instituto de Salud Carlos III., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

  • Ampuero, Javier|||0000-0002-8332-2122
  • Aller, Rocio
  • Gallego-Durán, Rocío
  • Crespo García, Javier|||0000-0001-8248-0172
  • Calleja, Jose Luis|||0000-0002-2265-6591
  • García-Monzón, Carmelo
  • Gómez-Camarero, Judith
  • Caballería, Joan
  • Lo Iacono, Oreste
  • Ibáñez Samaniego, Luis|||0000-0002-0309-2727
  • García-Samaniego, Javier|||0000-0002-9974-0855
  • Albillos, Agustín|||0000-0001-9131-2592
  • Francés, Rubén
  • Fernández-Rodríguez, Conrado
  • Maya-Miles, Douglas|||0000-0002-0669-6526
  • Diago, Moises|||0000-0002-8583-2433
  • Poca Sans, Maria|||0000-0002-0235-1395
  • Andrade, Raúl J.
  • Latorre, Raquel
  • Jorquera, Francisco|||0000-0002-1799-2881
  • Morillas Cunill, Rosa Ma|||0000-0001-9117-5049
  • Escudero-García, Desamparados
  • Hernandez-Guerra, Manuel|||0000-0002-3478-9981
  • Pareja-Megia, María Jesús
  • Banales, Jesus|||0000-0002-5224-2373
  • Aspichueta, Patricia
  • Benlloch, Salvador|||0000-0002-0794-6937
  • Rosales, José Miguel
  • Turnes, Juan|||0000-0001-8426-6145
  • Romero-Gómez, Manuel|||0000-0001-8494-8947
Background: MASLD can manifest as hepatocellular damage, which can result in mild elevation of aminotransferases. However, in some patients, MASLD presents with cholestatic pattern. Objective: To assess the impact of the biochemical pattern on the natural course of MASLD, including liver damage in histology, the accuracy of non-invasive tests(NITs), and prognosis. Methods: Multicenter study enrolling 2156 patients with biopsy-proven MASLD, who were classified based on their[ALT/ULN)]/[(ALP/ULN)] levels at the time of biopsy: (a) hepatocellular pattern(H),.